| Cash Flow | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Proceeds from sales and maturities of investments | 9,640 | 6,866 | 3,534 | 7,634 |
| Purchases of investments | 11,045 | 7,186 | 3,552 | 12,677 |
| Purchases of property and equipment | 2,048 | 1,350 | 743 | 2,013 |
| Acquisitions | 429 | 139 | 20 | 85 |
| Other | -9 | -23 | -19 | -75 |
| Net cash used in investing activities | -3,873 | -1,786 | -762 | -7,066 |
| Commercial paper borrowings (repayments), net | -872 | 921 | -859 | 600 |
| Proceeds from issuance of short-term loan | - | - | - | 0 |
| Repayment of short-term loan | - | - | - | 0 |
| Proceeds from issuance of long-term debt | 3,969 | 0 | - | 4,959 |
| Repayments of long-term debt | 3,609 | 762 | 743 | 1,706 |
| Repurchase of common stock | 0 | 0 | 0 | 3,023 |
| Dividends paid | 2,552 | 1,706 | 840 | 2,535 |
| Proceeds from exercise of stock options | 308 | 191 | 144 | 342 |
| Payments for taxes related to net share settlement of equity awards | 145 | 125 | 11 | 181 |
| Other | -7 | -45 | -23 | -22 |
| Net cash used in financing activities | -2,908 | -1,526 | -2,332 | -1,566 |
| Net income (loss) | -1,195 | 2,795 | 1,782 | 2,963 |
| Stock-based compensation | 400 | 262 | 126 | 403 |
| Loss on sale of subsidiary | -236 | -236 | -236 | - |
| Restructuring charges (impairment of long-lived assets) | 0 | - | - | 840 |
| Deferred income taxes and other items | -440 | -283 | -169 | -912 |
| Accounts receivable, net | 7,537 | 4,139 | 3,053 | 986 |
| Inventories | 982 | -671 | -722 | -355 |
| Other assets | 588 | 969 | 1,101 | 850 |
| Accounts payable and pharmacy claims and discounts payable | 5,052 | 3,831 | 2,619 | 2,169 |
| Health care costs payable and other insurance liabilities | 734 | -34 | 364 | 2,878 |
| Other liabilities | 2,868 | 1,758 | 1,876 | -3,063 |
| Goodwill impairment | 5,725 | - | - | - |
| Gain on deconsolidation of subsidiary | 483 | - | - | - |
| Depreciation and amortization | 3,459 | 2,325 | 1,154 | 3,450 |
| Net cash provided by operating activities | 7,249 | 6,453 | 4,556 | 7,247 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 468 | 3,141 | 1,462 | -1,385 |
| Cash and cash equivalents at beginning of period | 8,884 | 8,884 | 8,884 | 8,525 |
| Cash and cash equivalents at end of period | 9,352 | 12,025 | 10,346 | 7,140 |
CVS HEALTH Corp (CVS)
CVS HEALTH Corp (CVS)